Biotechnology company Zealand Pharma (NASDAQ:ZEAL) has delivered positive topline results from the Phase 3 trial of glepaglutide for the treatment of short bowel syndrome (SBS).
The trial met its primary endpoint and the twice-weekly dosing regimen showed a statistically significant decrease in weekly parental support at 24 weeks.
The treatment was deemed safe and was well tolerated.
Is Zealand Pharma Stock Good?
The Street currently has a Moderate Buy consensus rating on Zealand stock alongside an average price target of $32 which indicates an 81.92% potential upside for ZEAL stock.
Read full Disclosure
